Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1015 • ACR Convergence 2021
Preclinical Investigation of the First-in-Class SIK2/SIK3 Inhibitor GLPG3970 in Models of Arthritis
Catherine Jagerschmidt¹, Stephanie Lavazais¹, Maikel Colli², Michael Drennan², Erik Verschueren², David Amantini¹, Nicolas Desroy¹ and Steve De Vos², ¹Galapagos SASU, Romainville, France, ²Galapagos NV, Mechelen, Belgium
Background/Purpose: Improved management of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) remains an unmet need. Salt-inducible kinases (SIKs) modulate immune cells by a dual mechanism…
Abstract Number: 1326 • ACR Convergence 2021
Epidemiology of Comorbidities in an Incident Psoriasis Cohort: A Population-Based Study
Paras Karmacharya¹, Rikesh Chakradhar², Alexis Ogdie³, John Davis², Kerry Wright², Megha M. Tollefson², Ali Duarte-Garcia², Delamo Bekele², Hilal Maradit Kremers², Floranne Ernste², Tina Gunderson², Cassondra Hulshizer² and Cynthia Crowson⁴, ¹Mayo Clinic, Rochester MN; Vanderbilt University, Nashville, TN, ²Mayo Clinic, Rochester, MN, ³University of Pennsylvania, Philadelphia, PA, ⁴Mayo Clinic, Eyota, MN
Background/Purpose: Psoriasis, a chronic immune-mediated skin disease affecting 2-4% of the US population, is increasingly recognized as a systemic inflammatory disorder associated with cardiometabolic and…
Abstract Number: 1343 • ACR Convergence 2021
Guselkumab Treatment Modulates Core Psoriatic Arthritis Gene Expression in Two Phase 3 Clinical Trials (DISCOVER-1 and -2)
Stefan Siebert¹, Kristen Sweet², Christopher Ritchlin³, Elizabeth Hsia⁴, Alexa Kollmeier⁵, Xie Xu⁴, Qingxuan Song² and Michelle Miron², ¹University of Glasgow, Glasgow, United Kingdom, ²Janssen Research & Development LLC, Spring House, PA, ³Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC, La Jolla, CA
Background/Purpose: Guselkumab (GUS), an anti-IL-23 p19-subunit monoclonal antibody, demonstrated efficacy vs placebo (PBO) in reducing signs and symptoms of PsA in the phase-3 DISCOVER-1 &…
Abstract Number: 1359 • ACR Convergence 2021
Risk of Respiratory Tract Infections with Biologic and Targeted Synthetic Antirheumatic Agents in Psoriatic Arthritis: A Systematic Review and Network Meta-analysis
Yi-Shao Liu¹, Jawad Bilal², Muhammad Ajmal², Syed Arsalan Ahmed Naqvi³, Zaina Shahid⁴, Kaneez Zahra Rubab Khakwani², Farva Gondal⁵, Irbaz Bin Riaz⁶, Sandipan Bhattacharjee¹, Roxanne Bogucka¹ and C. Kent Kwoh⁷, ¹University of Texas at Austin, Austin, TX, ²University of Arizona, Tucson, AZ, ³Dow University of Health Sciences, Karachi, Pakistan, ⁴Lehigh Valley Health Network, Allentown, PA, ⁵University of Arizona College of Medicine, Tucson, AZ, ⁶Mayo Clinic, Phoenix, AZ, ⁷University of Arizona College of Medicine, Tuscon, AZ
Background/Purpose: A variety of biologic and targeted synthetic disease modifying antirheumatic agents have been widely used among patients with psoriatic arthritis (PsA). Due to the…
Abstract Number: 1777 • ACR Convergence 2021
Association of Opioid Use and Opioid-Related Costs with Patient-Reported Outcomes in Patients with Psoriatic Arthritis or Ankylosing Spondylitis
Alexis Ogdie-Beatty¹, Mark Hwang², Phani Veeranki³, Alexandria Portelli³, Jason Shafrin³, Sofia Pedro⁴, Esther Yi⁵, Steven Hass⁶ and Kaleb Michaud⁷, ¹University of Pennsylvania, Philadelphia, PA, ²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ³PRECISIONheor, Los Angeles, CA, ⁴Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁵Novartis Pharmaceuticals Corporation, Weehawken, NJ, ⁶H.E. Outcomes, LLC, Los Angeles, CA, ⁷University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) experience chronic pain due to inflammatory attributes of their disease. Nonsteroidal anti‑inflammatory drugs and biologics…
Abstract Number: 1794 • ACR Convergence 2021
Application of Treat to Target and Impact of Sustained Low Disease Activity or Remission on Function in Psoriatic Arthritis Patients
Proton Rahman¹, Regan Arendse², Philip Baer³, Michel Zummer⁴, Emmanouil Rampakakis⁵, Allen Lehman⁶, Meagan Rachich⁶, Francois Nantel⁷ and Odalis Asin-Milan⁶, ¹Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ²University of Saskatchewan, Saskatoon, SK, Canada, ³Baer Weinberg MPC, Scarborough, ON, Canada, ⁴CH Maisonneuve-Rosemont, Montréal, QC, Canada, ⁵JSS Medical Research, Montréal, QC, Canada, ⁶Janssen Inc., Toronto, ON, Canada, ⁷., Montréal, QC, Canada
Background/Purpose: Previous analyses have identified enrolment year as an independent predictor of real-world retention on anti-TNF treatment whereby patients enrolled in later periods were more…
Abstract Number: 1811 • ACR Convergence 2021
Efficacy of Guselkumab Across BASDAI Components in Treating Axial-Related Symptoms of Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-controlled Studies
Frank Behrens¹, Philip Mease², Philip S Helliwell³, May Shawi⁴, Wim Noel⁵, Soumya Chakravarty⁶, Alexa Kollmeier⁷, Xie Xu⁸, Stephen Xu⁸, Yanli Wang⁸ and Xenofon Baraliakos⁹, ¹CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine & Pharmacology, Goethe University Hospital, Frankfurt, Germany, ²Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁵Janssen Pharmaceutica, Vilvoorde, Belgium, ⁶Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, ⁷Janssen Research & Development, LLC, La Jolla, CA, ⁸Janssen Research & Development, LLC, Spring House, PA, ⁹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Guselkumab (GUS), an anti-interleukin-23p19 subunit monoclonal antibody, is approved to treat psoriatic arthritis (PsA). Post hoc analyses of DISCOVER-1&2 suggested that GUS may be…
Abstract Number: 1830 • ACR Convergence 2021
Discontinuation of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis and Psoriasis
Sophia Wolfe¹, Elizabeth Cheng², Kavya Ganuthula¹, Meika Fang³, Gail Kerr⁴, Jessica Walsh⁵, Elizabeth Chang⁶, Siba Raychaudhuri⁷, Kyle Brees², Robert Dellavalle¹, Andreas Reimold⁸ and Liron Caplan⁹, ¹Rocky Mountain Regional VAMC/University of Colorado School of Medicine, Aurora, CO, ²Rocky Mountain Regional VAMC, Aurora, CO, ³David Geffen School of Medicine at UCLA/West Los Angeles Veterans Affairs Medical Center (VAMC), Los Angeles, CA, ⁴Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC, ⁵Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ⁶Phoenix VAMC, Phoenix, AZ, ⁷Sacramento Veterans Affairs Medical Center (VAMC)/University of California-Davis Health, Davis, CA, ⁸University of Texas – Southwestern Medical Center/Dallas Veterans Affairs Medical Center (VAMC), Dallas, TX, ⁹Rocky Mountain Regional Veterans Affairs Medical Center (VAMC)/University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease of the joints and skin that affects 1/1000 people in the US. Tumor necrosis factor-alpha (TNF-α)…
Abstract Number: 0046 • ACR Convergence 2021
Psoriatic Arthritis Skin Is Transcriptionally Different to Psoriasis Skin and Enriched in Immunoglobulin Transcripts
Hanna Johnsson¹, John Cole¹, Stefan Siebert¹, Iain McInnes² and Gerard Graham¹, ¹University of Glasgow, Glasgow, United Kingdom, ²University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom
Background/Purpose: Up to 30% of patients with psoriasis develop psoriatic arthritis (PsA). The traditional assumption is that the skin disease is the same in both…
Abstract Number: 0205 • ACR Convergence 2021
An Observational Study from the Perspective of Rheumatology in the Management of Patients with Psoriatic Arthritis in Turkey – LOOP Study
Ediz Dalkilic¹, Dilek Solmaz², Orhan Kucuksahin³, Erhan Capkin⁴, Mehmet Emin Derin⁵, Didem Arslan⁶, Fatih Noyan⁷, Nihan Belkis Coskun¹, Sadiye Murat⁸, Omer Faruk Sendur⁹, Meltem Alkan Melikoglu¹⁰, Savas Gursoy¹¹, Taciser Kaya¹², Ali Sahin¹³, Murat Karkucak⁴, Timur Pirildar¹⁴, Mustafa Ender Terzioglu¹⁵, Cemal Bes¹⁶ and Servet Akar², ¹Uludag University, School of Medicine – Bursa, Turkey, Bursa, Turkey, ²Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ³Ankara State Hospital, School of Medicine, Ankara, Turkey, ⁴Karadeniz Technical University, School of Medicine, Trabzon, Turkey, ⁵Sivas Numune Hospital, Sivas, Turkey, ⁶Cukurova University, School of Medicine – Adana, Turkey, Adana, Turkey, ⁷Nazilli State Hospital – Aydın, Turkey, Aydin, Turkey, ⁸Istanbul Medeniyet University, Goztepe Training and Research Hospital, İstanbul, Turkey, ⁹Adnan Menderes University, School of Medicine, Aydin, Turkey, ¹⁰Ataturk University, School of Medicine, Erzurum, Turkey, ¹¹Gaziantep University, School of Medicine – Gaziantep, Turkey, Gaziantep, Turkey, ¹²Saglik Bilimleri University, Izmır Bozyaka Trainig and Research Hospital – Izmir, Turkey, Izmir, Turkey, ¹³Sivas Cumhuriyet University, School of Medicine, Sivas, Turkey, ¹⁴Celal Bayar University, School of Medicine – Manisa, Turkey, Manisa, Turkey, ¹⁵Akdeniz University, School of Medicine, Antalya, Turkey, ¹⁶Saglik Bilimleri University, Basaksehir Cam and Sakura State Hospital – Istanbul, Turkey, Istanbul, Turkey
Background/Purpose: Available evidence suggests that timely and effective management of patients with psoriatic arthritis (PsA) can improve long-term outcomes. Current information on the factors which…
Abstract Number: 0577 • ACR Convergence 2021
Comorbidity Burden as Scored Using the Rheumatic Disease Comorbidity Index (RDCI) Is Associated with Varying Treatment Patterns in Patients with Inflammatory Arthritis – a Study Using the EHR-Derived Rheumatic and Arthritis Disease Information Registry (RADIR)
Diviya Rajesh, Deanna Jannat-Khah, Huong Do, Jonah Levine, Medha Barbhaiya, Lisa Mandl and Vivian Bykerk, Hospital for Special Surgery, New York, NY
Background/Purpose: Higher comorbidity burden (CB) has been associated with treatment choices in RA, but not assessed in populations including multiple forms of inflammatory arthritis (IA)…
Abstract Number: 1054 • ACR Convergence 2021
Metabolomics as an Innovative Tool for Cardiac Risk Stratification in Patients with Rheumatic Diseases: Results from a Pilot Study
Sorwe Mojtahed Poor¹, Lisa Hahnefeld², Frank Behrens³, Harald Burkhardt⁴, Michaela Köhm⁵, Geisslinger Gerd⁶ and Gurke Robert⁷, ¹University hospital Frankfurt Devision Rheumatology and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany, ²pharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany, Frankfurt, Germany, ³Rheumatology & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Frankfurt/Main, Germany, ⁴University hospital Frankfurt Devision Rheumatology and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, ⁵University hospital Frankfurt Devision Rheumatology and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, ⁶Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, ⁷pharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany
Background/Purpose: Patients with rheumatic diseases (RMD) face an increased cardiovascular (CV) mortality compared to the general population. Still, risk stratification based on traditional cardiovascular risk…
Abstract Number: 1327 • ACR Convergence 2021
Impact of BMI on Treatment Response Among PsA Patients Initiating TNF Inhibitors, IL17 Inhibitors and Oral Small Molecules
Emily Purcell¹, Soumya Reddy², Jessica Walsh³, Jose Scher⁴, Ethan Craig⁵, Elaine Husni⁶ and Alexis Ogdie¹, ¹University of Pennsylvania, Philadelphia, PA, ²NYU School of Medicine, New York, NY, ³Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ⁴New York University School of Medicine, New York, NY, ⁵University of Pennsylvania, Wallingford, PA, ⁶Cleveland Clinic, Cleveland, OH
Background/Purpose: Obesity is associated with poor response to treatment in patients with psoriatic arthritis (PsA), however, available data are mostly focused on tumor necrosis factor…
Abstract Number: 1344 • ACR Convergence 2021
Impact of Achieving Minimal Disease Activity on Patient-Reported Outcome Measures and Disease Activity Among Patients with Psoriatic Arthritis Treated with Biologic and Targeted Synthetic DMARDs
Alexis Ogdie¹, Robert McLean², Maya Marchese², Taylor Blachley², Laura Anatale-Tardiff³, Christopher Saffore⁴, Kevin Douglas⁵, Danny Quach⁵ and Philip Mease⁶, ¹University of Pennsylvania, Philadelphia, PA, ²CorEvitas, LLC, Waltham, MA, ³CorEvitas, Waltham, MA, ⁴AbbVie, North Chicago, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: Minimal disease activity (MDA) is a common goal for disease control when managing PsA. The aim of this study was to assess the association…
Abstract Number: 1360 • ACR Convergence 2021
Ultrasound Demonstrates Continued Improvement in Psoriatic Arthritis Synovitis and Enthesitis with Secukinumab: 52-week Results from a Phase III Study
Maria Antonietta D'Agostino¹, Georg Schett², Corine Gaillez³, Carlos Guerrero⁴, PETRA HANOVA⁵, Tomas Cazenave⁶, Maria S. Stoenoiu⁷, Marina Backhaus⁸, Gael Mouterde⁹, Maarten Boers¹⁰, Anne-Marie Duggan¹¹, Punit Goyanka¹² and Philip Conaghan¹³, ¹Rheumatology, Fondazione Policlinico Universitario “Gemelli”, IRCCS, Rome, Italy, ²Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany, ³Novartis Pharma AG, Basel, Switzerland, ⁴Dermatologico Country, Jalisco, Mexico, ⁵Department of Rheumatology, Institute of Rheumatology, Prague, Czech Republic, ⁶Instituto de Rehabilitación Psicofisica, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁷Rheumatology department, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ⁸Department of Internal Medicine, Rheumatology and Clinical Immunology, Park-Klinik Weissensee Academic Hospital of the Charité, Berlin, Germany, Berlin, Germany, ⁹Rheumatology department, CHU Montpellier, Montpellier, France, ¹⁰Department of Epidemiology and Data Science, and Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ¹¹Novartis Ireland Limited, Dublin, Ireland, Dublin, Ireland, ¹²Novartis Healthcare Pvt Ltd, Hyderabad, India, Hyderabad, India, ¹³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Power Doppler ultrasound (PDUS) is a sensitive non-invasive imaging tool to visualize a wide range of articular and periarticular inflammation in psoriatic arthritis (PsA).1,2…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].